Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids

Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes

(2010) Satoshi Yamaori et al.   BIOCHEMICAL PHARMACOLOGY

Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation

(2010) E. T. Ogburn et al.   DRUG METABOLISM AND DISPOSITION

Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products

(2010) Nahoko Uchiyama et al.   Forensic Toxicology

Possible involvement of Cyp3a enzymes in the metabolism of tetrahydrocannabinols by mouse brain microsomes

(2010) Kazuhito Watanabe et al.   Forensic Toxicology

Pattern of poisoning in Japan: selection of drugs and poisons for systematic toxicological analysis

(2010) Keiko Kudo et al.   Forensic Toxicology

Metabolism of α-thujone in human hepatic preparationsin vitro

(2010) Khaled Abass et al.   XENOBIOTICA

Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6

(2009) Sui-Lin Mo et al.   CURRENT DRUG METABOLISM

Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6

(2009) Yuan Di et al.   CURRENT DRUG METABOLISM

Identification of a cannabimimetic indole as a designer drug in a herbal product

(2009) Nahoko Uchiyama et al.   Forensic Toxicology

Adverse health effects of non-medical cannabis use

(2009) Wayne Hall et al.   LANCET

Decreased Susceptibility of the Cytochrome P450 2B6 Variant K262R to Inhibition by Several Clinically Important Drugs

(2008) J. C. Talakad et al.   DRUG METABOLISM AND DISPOSITION